abstract |
Provided are fixed-dose apolipoprotein formulations effective to prevent and/or therapeutically manage diseases or conditions (including, but not limited to, cardiovascular disease), acute coronary syndrome, atherosclerosis , unstable angina and myocardial infarction. More specifically, the fixed-dose apolipoprotein formulation exhibited relatively reduced inter-patient variability than the weight-adjusted dose. Typically, the apolipoprotein preparation is a reconstituted high density lipoprotein preparation comprising ApoAl, one or more lipids such as phosphatidylcholine, sphingomyelin and/or phosphatidylglycerol and optionally a detergent such as Cholate does not induce hepatotoxic levels. |